Literature DB >> 9818314

Gadobenate dimeglumine (Gd-BOPTA). An overview.

M A Kirchin1, G P Pirovano, A Spinazzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9818314     DOI： 10.1097/00004424-199811000-00003

Source DB:  PubMed          Journal:  Invest Radiol        ISSN： 0020-9996            Impact factor:   6.016


× No keyword cloud information.
  53 in total

1.  Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors:  M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal:  Ultrasound       Date:  2013-12-13

Review 2.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 3.  MRA of abdominal vessels: technical advances.

Authors:  Henrik J Michaely; Olaf Dietrich; Kambiz Nael; Sabine Weckbach; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Eur Radiol       Date:  2006-05-24       Impact factor: 5.315

4.  Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Authors:  C S Peña; S Saini; R L Baron; B A Hamm; G Morana; R Caudana; A Giovagnoni; A Villa; A Carriero; D Mathieu; M W Bourne; M A Kirchin; G Pirovano; A Spinazzi
Journal:  Korean J Radiol       Date:  2001 Oct-Dec       Impact factor: 3.500

Review 5.  [Diagnostic radiology of liver tumors. Part 1: General disease aspects and radiological procedures].

Authors:  G Layer; M Bohrer
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

6.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

7.  Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.

Authors:  Daniel Stocker; Stefanie Hectors; Octavia Bane; Naik Vietti-Violi; Daniela Said; Paul Kennedy; Jordan Cuevas; Guilherme M Cunha; Claude B Sirlin; Kathryn J Fowler; Sara Lewis; Bachir Taouli
Journal:  Eur Radiol       Date:  2021-05-27       Impact factor: 5.315

8.  Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.

Authors:  Ricarda Rühl; Lutz Lüdemann; Anna Czarnecka; Florian Streitparth; Max Seidensticker; Konrad Mohnike; Maciej Pech; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2010-05-27       Impact factor: 3.481

9.  Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.

Authors:  Yulri Park; Seong Hyun Kim; Seung Hoon Kim; Yong Hwan Jeon; Jongmee Lee; Min Ju Kim; Dongil Choi; Won Jae Lee; Heejung Kim; Ji Hyun Koo; Hyo Keun Lim
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

Review 10.  Contrast agents for hepatic MRI.

Authors:  Giovanni Morana; Elisabetta Salviato; Alessandro Guarise
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.